Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib in the Treatment of Palmoplantar Pustulosis
NCT07270003Recruiting
- Sponsor
- Xijing Hospital
- Start
- Oct 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ivarmacitinib in palmoplantar pustulosis (PPP), sponsored by Xijing Hospital. Primary endpoint: PPPASI50 response rate at 12 weeks. Started Oct 2025; status: recruiting.
02
Drugs
ivarmacitinib
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT07270003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07270003.